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Abstract
Background: A function for the microRNA (miRNA) pathway in vascular development and
angiogenesis has been firmly established. miRNAs with selective expression in the vasculature are
attractive as possible targets in miRNA-based therapies. However, little is known about the
expression of miRNAs in microvessels in vivo. Here, we identified candidate microvascular-
selective miRNAs by screening public miRNA expression datasets.
Methods: Bioinformatics predictions of microvascular-selective expression were validated with
real-time quantitative reverse transcription PCR on purified microvascular fragments from
mouse. Pericyte expression was shown with in situ hybridization on tissue sections. Target sites
were identified with 3′ UTR luciferase assays, and migration was tested in a microfluid chemotaxis
chamber.
Results: miR-145, miR-126, miR-24, and miR-23a were selectively expressed in microvascular
fragments isolated from a range of tissues. In situ hybridization and analysis of Pdgfb retention
motif mutant mice demonstrated predominant expression of miR-145 in pericytes. We identified
the Ets transcription factor Friend leukemia virus integration 1 (Fli1) as a miR-145 target, and
showed that elevated levels of miR-145 reduced migration of microvascular cells in response to
growth factor gradients in vitro.
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MicroRNAs (miRNAs) are short endogenous RNAs that
regulate gene expression through translational repression of
specific target mRNA transcripts. miRNAs are transcribed
by RNA polymerase II, either from dedicated genes or as
parts of introns in host protein coding genes [1]. Maturation
begins with trimming of the immediate transcribed product
into a stem-loop structure (the pre-miRNA) by the nuclear
enzyme Drosha. This is followed by cleavage by the cytosolic
enzyme Dicer into a short 19- to 25-bp double-stranded RNA
[2]. Normally, one strand is quickly degraded, while the
other (the mature miRNA) associates with the RNA-induced
silencing complex (RISC). This riboprotein complex has the
ability to recognize and silence target mRNAs, usually
through imperfect complementarity to sequence elements in
the 3′ untranslated region (UTR).
Several recent studies establish a role for miRNA in vascular
development and angiogenesis [3]. Dicer-deficient mice die
during early embryonic development and display impaired
angiogenesis and yolk sac formation [4], whereas endo-
thelial-specific inactivation of Dicer reduces postnatal angio-
genesis [5]. Small interfering RNA knockdown of Dicer or
Drosha leads to reduced endothelial proliferation, sprouting
and network formation in vitro [6,7]. Moreover, the expres-
sion of angiogenesis-related genes, such as Vegf, Flt1, Kdr
and Tie1, is altered in Dicer mutant embryos [4] and follow-
ing Dicer knockdown in cultured endothelial cells (ECs) [7].
However, relatively little is known about the function of indi-
vidual miRNAs in the microvasculature. miR-126 controls
VCAM-1 (vascular cell adhesion molecule-1) expression in
human umbilical vein endothelial cells (HUVECs) [8] and
was recently shown to regulate vascular integrity and
angiogenesis in vivo [9-11]. Others, including let-7f, miR-27b
[6], miR-221, and miR-222 [12], have been shown to modu-
late angiogenesis in vitro and overexpression or inhibition of
miR-378 [13], the miR-17-92 cluster [14] and miR-296 [15]
affects angiogenesis in mouse engrafted tumors. Some of
these studies show direct regulation of a target gene, but
downstream mechanisms are in many cases unknown.
In several of the above mentioned studies, microarrays were
used to identify mature miRNAs highly expressed in ECs.
These experiments were all performed in vitro on HUVECs
and aimed at the identification of highly expressed miRNAs
rather than specific/selective expression [6-8,12], or on
embryoid body (EB) cultures [10]. Here, we used publicly
available expression datasets to screen for miRNAs with
enriched expression in the mature microvasculature in vivo.
Selected candidates were evaluated using real-time quantita-
tive reverse transcription PCR (qRT-PCR) on mature blood
vessel fragments isolated from mouse tissues. miR-145,
miR-126, miR-24 and miR-23a were consistently enriched in
adult microvessels. We further showed that miR-145 regula-
ted the endothelial Ets factor Fli1 and that miRNA-145
reduced cell migration in response to growth factor gradients.
Methods
Bioinformatics
A total of 47,232 small RNA clone sequences distributed
over 65 tissues, including the kidney glomerulus, were ob-
tained from a recent survey [16]. Two compendia with
microarray data from mouse tissues, including lung [17,18],
were downloaded from the NCBI Gene Expression Omnibus
repository. To ensure consistent mapping between datasets,
clone/probe sequences were re-annotated against miRBase
release 10.1 [19] using a proprietary Matlab (Mathworks Inc.
Natick, MA, USA) script. For each mature miRNA, a P-value
for over-representation in the glomerulus library compared
to the other tissues was calculated using Fisher’s exact test.
Likewise,  P-values for differential expression in the lung
compared to remaining adult tissues were determined using
the Student’s t-test. The t-test provides a useful metric of
differential tissue expression, although the formal
requirements for the underlying distribution of the data may
not be completely met [20]. Genomic localization of miRNAs
was evaluated using data derived from the UCSC browser
(July 2007 assembly) [21].
Isolation of CD31+ microvascular fragments and
TaqMan qRT-PCR
Microvascular fragments were isolated from mouse tissues
and embryonic stem cell cultures using mechanical and
enzymatic digestion followed by incubation with magnetic
Dynabeads coated with anti-CD31 (anti-platelet endothelial
cell adhesion molecule (PECAM)). The procedure was per-
formed essentially as described previously [22]. All mice
were adult (8 to 12 weeks old) males, either wild-type
C57BL/6 or Pdgfbret/ret backcrossed for seven generations
onto a C57BL/6 background [23]. RNA from vascular frag-
ments and remaining tissue was prepared using miRNeasy
Mini spin columns (Qiagen, Hilden, Germany). Samples
were quantified with a NanoDrop spectrophotometer
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Conclusions:  miR-126, miR-24 and miR-23a are selectively expressed in microvascular
endothelial cells in vivo, whereas miR-145 is expressed in pericytes. miR-145 targets the
hematopoietic transcription factor Fli1 and blocks migration in response to growth factor
gradients. Our findings have implications for vascular disease and provide necessary information
for future drug design against miRNAs with selective expression in the microvasculature.(Thermo Scientific Corporation, Waltham, MA, USA) and
cDNA was synthesized using equal amounts of RNA in each
reaction (High-Capacity Reverse Transcription Kit or
MicroRNA Reverse Transcription Kit, Applied Biosystems,
Foster City, CA, USA). Expression levels were determined
using pre-designed TaqMan assays (Applied Biosystems) on
a 7900HT real-time PCR system, according to the manufac-
turer’s instructions. Relative levels were calculated using the
2-Ct method. Fli1 mRNA levels were determined using SYBR
Green quantitative qPCR (95°C, 55°C, 72°C, 40 cycles) using
the following primers: 5′-TATCAGATCCTGGGGCCAAC-3′
and 5′-CTCATCAGGGTCCGTCATTT-3′.
Differentiation of embryonic stem cells into vascular
sprouts
The murine embryonic stem cell line R1 [24] was routinely
cultured on growth arrested mouse embryonic fibroblasts in
stem cell medium composed of DMEM-Glutamax (Invitro-
gen, Carlsbad, CA, USA) supplemented with 25 mM HEPES
pH 7.4, 1.2 mM sodium pyruvate, 19 mM monothioglycerol
(Sigma-Aldrich, St. Louis, MO, USA), 15% fetal bovine serum
(Gibco/Invitrogen, Carlsbad, CA, USA), and 1,000 U/ml
leukemia inhibitory factor (Chemicon International/Millipore,
Billerica, MA, USA). EBs were generated by aggregation of
stem cells in hanging drops in the absence of leukemia
inhibitory factor, as described previously [25]. Briefly, EBs
were collected after 4 days and seeded into 12-well dishes
onto a layer of 0.9 ml solidified collagen type I solution
composed of Ham’s F12 medium (Promocell, Heidelberg,
Germany), 6.26 mM NaOH, 20 mM HEPES, 0.117%
NaHCO3, 1% Glutamax-I (Gibco) and 1.5 mg/ml collagen I
(PureCol, Advanced BioMatrix, San Diego, CA, USA). Imme-
diately thereafter, a second layer of 0.9 ml collagen solution
was added on top and allowed to polymerize. After 3 hours,
0.9 ml of stem cell medium supplemented with vascular
endothelial growth factor A (VEGFA; PeproTech, Rocky Hill,
NJ, USA), at a final concentration of 30 ng/ml, was added to
induce angiogenic sprouting. The medium was replaced
every second day. EBs were excised from the gels at day 14
and immediately processed for isolation of CD31+ vascular
fragments, as described above. NG2+ cells were isolated
with the same protocol using a rabbit anti-rat NG2 antibody
(Chemicon; AB5320), after depletion of CD31+ cells from
the cultures.
In situ hybridization and immunohistochemistry
In situ hybridization was performed using a 3′ DIG-labeled
miRCURY LNA probe to mouse miR-145 and miR-126
(Exiqon, Vedbaek, Denmark) as previously described [26].
For dual detection of miR-145 and the pericyte marker NG2,
the immunostaining was performed after development of the
in situ signal. Slides were washed in phosphate-buffered
saline, blocked with 3% donkey serum and 1% bovine serum
albumin in phosphate-buffered saline, then incubated with
rabbit anti-rat NG2 antibody (Chemicon; diluted 1/50)
overnight at 4°C, washed in phosphate-buffered saline, then
detected with Alexa488-conjugated donkey anti-rabbit IgG
(Invitrogen; diluted 1/200).
Vascular aortic endothelial cell culture, scratch wound
and proliferation assays
Mouse vascular aortic endothelial cells (VAECs; Dominion
Pharmakine, Derio–Bizkaia, Spain) were cultured in RPMI
1640 media (Sigma) supplemented with 10% fetal calf serum
(Gibco), 1 μg/ml dexamethasone, 10 U/ml heparin, 50 U/ml
penicillin/streptomycin and 75 μg/ml EC growth factor
supplement (Sigma). For scratch wound migration assays,
cells were transfected by electroporation (Nucleofector
system, Basic Endothelial Cell Kit, Amaxa Inc/Lonza group
ltd, Basel, Switzerland) using 0.5 μg of synthetic mature
miR-145 double-stranded RNA (dsRNA; Pre-miR-145;
Applied Biosystems) or negative control dsRNA (Stealth
siRNA negative control; Applied Biosystems), seeded onto 6-
well plates and cultured for 48 hours. Scratch wounds were
generated in the cell monolayer using a pipet tip and each
wound was photographed at 0 and 24 hours. Wound widths
were evaluated blindly at both time-points and the average
amount of closure was determined for each replicate
transfection. VAEC proliferation was measured by quantifi-
cation of 5′-bromo-2′-deoxyuridine (BrdU) incorporation.
Cells were pulsed for 4 hours with 20 μM BrdU and DNA
synthesis was determined using a colorimetric ELISA
(Calbiochem/Merck, Darmstadt, Germany) according to the
manufacturer’s instructions. Absorbance was measured at
dual wavelengths of 450 to 540 nm.
Microfluidic migration chamber
Migration of HUVECs in response to a stable gradient of
VEGFA-165 (PeproTech; 0 to 50 ng/ml over a distance of
400 µm) or BJ-hTERT (human foreskin fibroblast) cells in
response to platelet-derived growth factor (PDGF)-BB (0-
20 ng/ml) was examined using a microfluidic chemotaxis
chamber, essentially as previously described [27]. HUVECs
were transferred to 3-cm culture dishes coated with type A
gelatin from porcine skin (Sigma) and were allowed to attach
to the dish in EGM-2MV medium (Lonza) with serum and
supplement growth factors. After 2 hours the medium was
aspirated and the cells were transfected with 0.5 μg of Pre-
miR negative control, Pre-miR-145, Anti-miR negative
control or Anti-miR-145 (Applied Biosystems) using siPORT
NeoFX (Ambion, Austin, TX, USA) in serum and growth
factor free EBM-2 medium (Lonza) containing 0.2% bovine
serum albumin. After 24 hours the gradient experiment was
initiated. BJ-hTERT cells were cultured in minimal essential
medium (MEM, Invitrogen) containing 10% fetal calf serum
(Gibco), 1 mM sodium pyruvate (Gibco) and non-essential
amino acids (Gibco). Cells were transfected using electro-
poration (0.5 μg, Nucleofector system, Amaxa) and were
allowed to rest between 24 and 48 h before being seeded
onto gelatin A-coated culture dishes and serum starved
overnight, before onset of gradient. VEGFA-165 or the
PDGF-BB gradients were generated in serum-free cell
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or 4 hours (BJ-hTERT cells ) using a Cell Observer System
(Carl Zeiss AB, Stockholm, Sweden) fitted with a Zeiss
Axiovert 200 microscope, an AxioCam MRm camera, a
motorized X/Y stage, and an XL incubator with equipment
for temperature and CO2 control (Zeiss). Cells were kept in a
humidified atmosphere of 5% CO2 in air at 37°C during all
experiments. AxioVision software (Zeiss) was used for time-
lapse imaging and cell tracking.
Luciferase reporter assays
Oligonucleotides (65 bp) harboring wild-type or mutated
miR-145 binding sites from the mouse Fli1 3′ UTR (Additional
data file 1) were annealed and ligated into the HindIII and
SpeI sites of the pMIR-REPORT CMV-firefly luciferase
reporter vector (Applied Biosystems). All constructs were
verified by sequencing. HEK293 cells were seeded onto
24-well plates at a density of 50,000 cells/well and cultured
overnight in DMEM (10% fetal calf serum) without anti-
biotics. Cells were transfected with 60 ng of pMIR-REPORT,
8 ng of pRL-SV40 renilla luciferase control vector and
10 pmol of Pre-miR negative control or Pre-miR-145 using
Lipofectamine 2000 (Invitrogen) and luciferase activity was
assayed after 48 hours using the Dual-Luciferase Reporter
System (Promega, Madison, WI, USA).
Long mouse and human Fli1 3′ UTR fragments were
amplified by PCR using the following primers (numbers
indicate the position starting from the stop codon): 5′-AAC-
TAACACCAGTTGGCCTTC-3′ and 5′-CGTCAGGAGTGTCTG-
AGTTTG-3′ (1-704); 5′-GCTTCTTCTAGCTGAAGCCCATC-3′
and 5′-GTCAAATTATTTTACAACATGG-3′ (3-1,391). Ampli-
mers were cloned in psiCHECK-2 (Promega) to generate
Renilla luciferase-3′ UTR reporter constructs. Basal expres-
sion of firefly luciferase from the same plasmid served as an
internal control. HEK293T cells seeded in 96-well plates
were cotransfected with plasmid (50 ng per well) and synthetic
miRNA (0.25 to 2.5 pmol per well; Biomers, Ulm, Germany)
using Lipofectamine 2000. Luciferase activity was assayed
24 hours after transfection as described [28]. Nucleotides 2
and 4 in the seed region of three predicted miR-145 sites
within the mouse 3′ UTR fragment were mutated using
Multisite-Quickchange (Stratagene/Agilent, Santa Clara, CA,
USA). Results represent Renilla/firefly luciferase ratios from
four independent experiments performed in triplicates.
Statistical significance was evaluated using Student’s t-test.
Western blot analysis
VAECs were electroporated with either Pre-miR-145 or Pre-
miR negative control as described above. Nuclear extracts
were prepared using the CelLytic NuCLEAR kit (Sigma) at
72 hours post-transfection. Western blotting was performed
using a Fli1 antibody (Sc-356; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at 2 mg/ml and ECL reagents (Amer-
sham Biosciences/GE Healthcare Bio-Sciences, Uppsala,
Sweden). As a loading control, the membrane was stripped
and reprobed using a lamin A/C antibody (Sc-7293, Santa
Cruz Biotechnology) at a dilution of 1/1,500. Densitometric
analysis was performed using ImageJ software.
Results
Bioinformatic prediction of microvascular miRNAs
Protein-coding genes with selective expression in the
microvasculature were identified in a recent study based on
their enrichment in the lung and in the kidney glomerulus
[29]. Differential expression in both of these endothelium-
rich tissues minimized contamination by epithelial trans-
cripts and permitted identification of numerous known and
novel microvascular markers. Here we applied a similar
strategy to identify candidate microvascular-enriched miRNAs.
Data were gathered from three different sources: a set of
small RNA sequence libraries of varying sizes covering 65
mouse tissues, including the glomerulus [16], and two
compendia with microarray data from adult mouse tissues,
including lung [17,18] (Figure 1a). miRNAs were scored for
enrichment in glomerulus and lung and this formed the
basis of our selection (Additional data file 2).
Among those with favorable scores in this analysis, miR-126-
3p and miR-126-5p (the two mature forms of miR-126)
stood out as strongly enriched in both glomerulus and lung
(Figure 1b). Several other miRNAs also appeared as promis-
ing candidates for selective vascular expression, including
miR-145, miR-30d, miR-23b and miR-24 (within the dashed
lines in Figure 1b). miRNAs connected by thick grey lines in
the figure are co-localized in the genome (<10 kb) and likely
derive from the same polycistronic transcript [30].
Differential expression of miR-126, miR-145, miR-24,
and miR-23a in the mature microvasculature
Based on the above described in silico analyses, we chose to
further characterize the expression of miR-126-3p (the
predominant mature form of this miRNA, hereafter
referred to as miR-126), miR-145, miR-30d, miR-23b,
miR-24 and miR-23a; the latter being co-transcribed with
miR-24 [1]. Microvascular fragments were isolated from
adult mouse tissues using mechanical and enzymatic
digestion followed by separation using anti-CD31
(PECAM)-coated magnetic beads. RNA was prepared from
the fragments and the remaining tissue fractions. qRT-PCR
analysis showed that miR-126 was highly differentially
expressed in CD31+ fragments in all adult organs assayed,
with fragment-to-surrounding tissue ratios ranging from 90
to 250. These ratios are in parity with the endothelial
markers Cd31 and Kdr (Vegfr2/Flk1; Figure 2). The
remaining miRNAs were also enriched in vascular frag-
ments to varying degrees. In particular, miR-145 showed
consistent and high differential expression in microvessels
(24-, 7-, 75- and 18-fold for brain, muscle, skin and kidney,
respectively). In addition, miR-23a and miR-24 were
consistently differentially expressed, with enrichments
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showed weak or no enrichment across the panel.
miRNA expression during vascular formation
To evaluate miRNA expression in immature blood vessels,
CD31+ microvascular fragments were isolated from mouse
kidneys at embryonic day 14, as well as from VEGFA-
induced angiogenic sprouts formed in EB cultures. miR-126
showed strong enrichment in CD31+ fractions from both
tissues (Figure 3). miR-23a and miR-24 were enriched in
sprouts from EBs but not in fragments from embryonic day
14 kidneys. miR-145, in contrast, was predominantly
expressed in the leftover fractions. The pericyte marker
Pdgfrb showed a similar pattern with strong enrichment in
CD31+ fragments from adult tissues but not in embryonic
vascular fragments (Figures 2 and 3), which suggests that
miR-145 could be expressed by pericytes.
miR-145 is selectively expressed by pericytes
To test the hypothesis that miR-145 is expressed by peri-
cytes, CD31+ fragments were purified from the brains of
Pdgfb retention-motif mutant mice (Pdgfbret/ret) that lack a
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Genome Medicine 2009, 1:108
Figure 1
Identification of putative microvessel-enriched miRNAs using public
expression data. (a) Table of datasets included in the analysis. Mature
miRNAs were evaluated for enrichment in the lung in two datasets
(Thomson et al. [17] and Beuvink et al. [18]). Glomerular enrichment was
determined in an expression dataset derived by small RNA library
sequencing (Landgraf et al. [16]). All clone and probe sequences were re-
annotated against the miRBase microRNA repository [19]. (b) Scatter
plot showing mature miRNAs enriched in both the glomerulus (y-axis)
and lung (x-axis; using best value from the two microarray datasets).
miRNAs connected by thick grey lines are co-localized in the genome
(<10 kb) and likely to be co-transcribed.
Dataset Mature miRNAs Tissues/cell types
Annotation:
miRBase r10.1 579 n/a
Expression:
Landgraf et al small RNA sequence library 429 65
Thompson et al microarray dataset 115 7
Beuvink et al microarray dataset 136 8
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Figure 2
Differential expression of miRNAs in CD31+ vascular fragments isolated
from mature mouse organs. Anti-CD31-coated magnetic beads were used
to isolate microvascular fragments from adult (8 weeks) C57Bl/6 mouse
organs. cDNA was prepared from the fragments and the remaining tissue
using equal amounts of RNA, and miR-145 expression levels were
determined using TaqMan qRT-PCR. The figure shows average paired
expression ratios between fragments and surrounding tissue ± standard
error of the mean (n = 4, 3, 2 and 4 for brain, muscle, skin and kidney,
respectively). GAPDH, CD31 and VEGFR-2 (Flk1) TaqMan assays were
used as quality controls.
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Kidneystretch of basic amino acids in the carboxyl terminus of
PDGF-B. These mice display defective pericyte investment of
microvessels [23]. As expected, Pdgfrb mRNA levels were
reduced in Pdgfbret/ret vascular fragments compared to wild-
type mice (P = 0.001; Figure 4a). Expression of miR-145 was
also reduced in mutant microvessels (P = 0.008), whereas
no notable differences were observed for the other miRNAs.
These results gave further support to the idea that micro-
vascular miR-145 expression is derived primarily from
pericytes.
As a complementary approach, CD31+ ECs and NG2+
pericytes were isolated from EB cultures. Expression levels
were determined using qRT-PCR and the ratio of the signals
from the two fractions was determined. In accordance with
the pericyte markers, miR-145 expression was higher in
NG2+ cells compared to CD31+ cells (Figure 4b). In contrast,
the endothelial marker Cd31 and miR-126 were highly
enriched in the CD31+ fraction.
Next, we performed in situ hybridization on tissue sections
using probes specific to miR-145 and miR-126. As expected,
miR-145 stained smooth muscle cells in larger vessels
whereas miR-126 stained ECs (staining patterns in kidney
arteries are shown in Figure 4c,d). In brain parenchyma,
miR-145 showed staining in solitary scattered cells, consis-
tent with expression in pericytes (Figure 4f). Double staining
using an NG2 antibody confirmed co-expression of the two
molecules in brain capillaries (Figure 4g) and in small
caliber blood vessels in the kidney (Figure 4e). There was,
however, no detectable expression of miR-145 in pericytes in
the heart, where the expression was confined to arterioles
and larger vessels (Figure 4h). Compared to miR-145, NG2
staining indicated larger areas in kidney and brain micro-
vessels (Figure 4e,g). This suggests that miR-145 is expressed
by a subset of pericytes. However, this could also be explained
by NG2’s subcellular distribution in pericyte processes that
extend from the main cell body and cover the capillary cell
surface.
We conclude that miR-145 is selectively expressed in micro-
vessel pericytes whereas the remaining miRNAs are expressed
in ECs.
Fli1 is a target of miR-145
miRNA target prediction software was used to identify
possible targets for miR-145. The highest-scoring predicted
target using the miRanda algorithm [31] was the gene
encoding the Ets transcription factor Friend leukemia inte-
gration 1 (Fli1). Fli1 also scored favorably using picTar [32]
and TargetScan [33], the latter identifying four evolution-
arily conserved miR-145 binding sites in the Fli1 3′ UTR
(Figure 5a).
To evaluate if the predicated sites can bind miR-145 and
induce silencing, we generated a series of eight constructs,
each consisting of a CMV-luciferase reporter followed by a
portion of the Fli1 3′ UTR containing a wild-type or mutated
site. Transfection of a synthetic miR-145 mimic dsRNA (Pre-
miR-145) into HEK293 cells significantly reduced reporter
activity for all predicted sites (Figure 5b). Single base-pair
mutations reduced or abolished the effect of miR-145 on
reporter activity in all cases. An empty reporter vector,
lacking a cloned target site in the 3′ UTR, was not affected by
miR-145 overexpression.
Constructs with either a full length human or a long (700 bp)
fragment of the mouse Fli1 3′ UTR were generated to evalu-
ate the predicted sites in their natural sequence context.
Cotransfection with a miR-145 mimic significantly reduced
reporter activity compared to transfection without a miRNA
or with an unrelated miRNA (Figure 5c). The effect was
abolished when mutations were introduced in three out of
four predicted sites in the mouse 3′ UTR (Figure 5d).
An effect of miR-145 on endogenous Fli1 protein levels was
demonstrated in VAECs. Western blot analysis 72 hours
post-transfection of Pre-miR-145 showed that Fli1 protein
levels were decreased compared to cells treated with Pre-
miR negative control (Figure 5e). Since miRNAs can induce
both translational repression and target mRNA degradation,
we performed qRT-PCR to assess the expression of Fli1 mRNA
after introduction of Pre-miR-145 or Pre-miR negative
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Figure 3
miRNA expression in immature blood vessels. To investigate the
expression in immature vessels, microvascular fragments were isolated
with anti-CD31-coated magnetic beads from embryonic kidney (E14
kidney) and EBs with active sprouting angiogenesis (n = 3 for both kidney
and EB; error bars indicate standard error of the mean).
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Figure 4
Pericyte expression of miR-145. (a) To differentiate between pericyte and EC expression, vascular fragments were isolated from the brains of pericyte-
deficient Pdgfbret/ret mice using anti-CD31-coated magnetic beads. Bars show relative expression levels in CD31+ fragments from wild-type and Pdgfbret/ret
± standard error of the mean (n = 4 and 3, respectively). (b) CD31+ cells were isolated from EB cultures using magnetic beads. After depletion of
CD31+ cells, cells expressing the pericyte marker NG2 were isolated using the same protocol. Bars show the ratio of expression between NG2+ and
CD31+ fragments. Error bars indicate standard error of the mean (n = 3). (c-i) In situ hybridization (blue) against miR-145 (c,e-h) and miR-126 (d) with
double staining for NG2 (green) (e,g-h). (c) miR-145 in situ hybridization stains vascular smooth muscle cells (m, media) whereas (d) miR-126 stains ECs
(arrowheads) in kidney artery (scale bar, 25 μm). (e) High power magnification of a small vessel in kidney shows that a miR-145-positive cell (arrow)
expresses NG2 (scale bar, 5 μm). (f) miR-145 in situ hybridization labels solitary cells in adult brain (arrows; scale bar, 100 μm). (g) Double staining for
miR-145 (arrows) and NG2 show co-expression in cells tightly associated with small caliber (10 μm) capillaries in brain (scale bar, 50 μm). (h) miR-145
staining in the heart is confined to arterioles (arrowheads) whereas no expression was detected in NG2-positive cells in microvessels (arrows) (scale bar,
50 μm). (i) Negative control (without probe; scale bar, 100 μm).
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Translational repression without mRNA degradation has
been described for numerous miRNAs, and our findings are
consistent with a previous report suggesting that miR-145 is
primarily a repressor of translation [34]. VAECs were also
transfected with Anti-miR-145 in a loss-of-function experi-
ment. This did not affect Fli1 levels (data not shown), which
is consistent with low endogenous expression of miR-145 in
this cell type (Additional data file 3).
miR-145 modulates cell migration in vitro
In order to assess the role of miR-145, functional assays were
performed in human foreskin fibroblasts, and in ECs that
express Fli1. Cell migration is often guided by growth factor
gradients in vivo. PDGF-BB is known to stimulate migration
of several different cell types, including smooth muscle and
fibroblasts [35,36]. It is also a key regulator of pericytes in
vivo  [37]. We therefore investigated cell migration in
response to a stable gradient of PDGF-BB using a micro-
fluidic chemotaxis chamber. Human foreskin fibroblasts
(BJ-hTERT) were transfected with Pre-miR-145 or Pre-miR
negative control in gain-of-function experiments and with
Anti-miR-145 or Anti-miR-control in loss-of-function
experiments (expression levels of miR-145 in BJ-hTERT
cells are presented in Additional data file 3). Individual cells
were tracked using time-lapse microscopy during 3 hours
[27]. The average migrated distance per cell toward the high-
end of the PDGF-BB gradient was reduced by more than
50% in Pre-miR-145 transfected cells, whereas migration
perpendicular to the gradient was only slightly, and not
significantly, reduced (Figure 6a). Similarly, migration
towards the high-end of the gradient was reduced by Anti-
miR-145 (Figure 6b). Migration perpendicular to the
gradient was also significantly reduced by this treatment.
To investigate the effect of miR-145 on VEGFA-165-induced
migration, HUVECs were cultured in a stable gradient of
VEGFA-165. Control cells migrated consistently toward the
high-end of the gradient, whereas Pre-miR-145-transfected
cells exhibited a clear (>50%) reduction in migration in this
direction (Figure 6c). Migration perpendicular to the
gradient was not significantly reduced.
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Figure 5
Regulation of Fli1 by miR-145. (a) Four possible miR-145 binding sites
were identified in the Fli1 3′ UTR. Evolutionary conservation across four
mammalian species is shown. Seed regions are indicated by grey boxes. 
(b) Luciferase assays show that the predicted sites can mediate silencing
by miR-145. Approximately 60-bp regions containing wild-type (WT)
miR-145 binding sites in the Fli1 3′ UTR were cloned into pMIR-REPORT
vector (Applied Biosystems). Identical constructs with single base-pair
mutations (Mut) were generated (mutated bases, C to G, are indicated in
italics and bold in the sequences). HEK293 cells were co-transfected with
pMIR-REPORT and either negative control dsRNA or a synthetic miR-145
dsRNA (Pre-miR-145) and luciferase activity assayed after 48 hours. Signals
were normalized to the control groups. Error bars indicate standard error
of the mean (n = 2, P < 0.05 for control versus Pre-miR-145 with all WT
constructs). (c) Larger regions of the mouse and human Fli1 3′ UTRs (704
and 1,288 bp, respectively) were cloned into luciferase reporter vectors
and luciferase activity was assayed 24 hours after cotransfection with
synthetic miR-30a or miR-145 in HEK293 cells. Four replicate experiments
were performed and values shown are normalized to the empty (plasmid
only) transfections (P < 0.001 for both constructs, comparing empty and
miR-145 transfections). (d) Site-directed mutagenesis was applied to the
704-bp mouse Fli1 3′ UTR fragment. Two single base mutations were
introduced in each of the seed regions of predicted target sites 2 to 4.
Constructs were cotransfected with either synthetic let-7f (control) or
miR-145 and luciferase activity was assayed after 24 hours (n = 4). (e)
Relative Fli1 protein levels in VAECs were measured 72 hours post-
transfection with either Pre-miR-145 or a dsRNA control. Nuclear
extracts were prepared and expression was assayed by western blotting
followed by densitometric analysis. The membrane was re-probed with a
lamin A/C antibody as a loading control. Error bars indicate standard error
of the mean. (f) Fli1 mRNA levels in VAECs 72 hours post-transfection
were determined using qRT-PCR and normalized to GAPDH. Error bars
represent standard error of the mean (n = 4).
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Figure 6
Elevated levels of miR-145 leads to reduced microvasular cell migration. (a) Migration of BJ-hTERT cells was evaluated using a microfluidic chemotaxis
chamber. Individual cells, cultured in a stable PDGF-BB gradient (0 to 20 ng/ml over a distance of 400 μm), were tracked using time-lapse microscopy.
Cells were transfected with control dsRNA or Pre-miR-145 and average migrated distances toward the gradient and perpendicular to the gradient were
calculated. The bar graphs show average values from three independent experiments ± standard error of the mean (P-value obtained using the two-tail t-
test). The polar plots illustrate the direction of migration for individual cells in the control experiments (top) and in the Pre-miR-145 transfected cultures
(bottom). The radius of each 15 degree sector indicates the number of cells that migrated in this direction. A total of 285 and 239 cells were tracked for
the negative control and Pre-miR-145, respectively. (b) Migration of Bj-hTERT cells transfected with control single-stranded RNA or Anti-miR-145 in a
PDGF-BB gradient, as described above for Pre-miR-145. The bar graphs show average results from five independent experiments, and a total of 701 and
622 cells were tracked for the negative control and Anti-miR-145, respectively. (c) Migration of HUVECs in response to a VEGFA-165 gradient (0 to 50
ng/ml), as described above for PDGF-BB. Results are average values from three independent experiments, and a total of 185 and 191 cells were tracked
for the negative control and Pre-miR-145, respectively. (d) Migration of VAECs was evaluated using scratch wound assays. Cells were electroporated
with either a negative control dsRNA or a synthetic miR-145 dsRNA (Pre-miR-145) and cultured for 48 hours. A scratch wound was generated in the
cell monolayer and the degree of wound closure determined 24 hours later. The graph shows the mean migrated distance (difference in wound width
after 24 hours ± standard error of the mean, n = 3). Proliferative activity of VAECs 48 hours post-transfection was assessed by quantification of BrdU
incorporation. Cells were pulsed for 4 hours and incorporated BrdU was measured using a colorimetric ELISA (mean absorbance ± standard error of the
mean; n = 4).
Pre-miR-145
Neg. control
Pre-miR-145
Neg. control
M
e
a
n
 
d
i
s
t
a
n
c
e
p
e
r
 
c
e
l
l
 
(
µ
m
)
M
e
a
n
 
d
i
s
t
a
n
c
e
p
e
r
 
c
e
l
l
 
(
µ
m
)
P = 0.03
P = 0.02
P = 0.05
  5
  10
  15
  20
30
210
60
240
90
270
120
300
150
330
180 0
V
E
G
F
A
 
c
o
n
c
e
n
t
r
a
t
i
o
n
(b)
  5
  10
  15
  20
30
210
60
240
90
270
120
300
150
330
180 0
V
E
G
F
A
 
c
o
n
c
e
n
t
r
a
t
i
o
n
Neg. control
Pre-miR-145
0
10
20
30
40
50
0
10
20
30
40
50
60
70
Migration toward gradient
Migration perpendicular
to gradient
P = 0.07
(a)
Pre-miR-145
Neg. control
Pre-miR-145
Neg. control
M
e
a
n
 
d
i
s
t
a
n
c
e
p
e
r
 
c
e
l
l
 
(
µ
m
)
M
e
a
n
 
d
i
s
t
a
n
c
e
p
e
r
 
c
e
l
l
 
(
µ
m
)
Migration toward gradient
(d)
Migration toward gradient
Migration perpendicular
to gradient
P
D
G
F
-
B
B
 
c
o
n
c
e
n
t
r
a
t
i
o
n
P
D
G
F
-
B
B
 
c
o
n
c
e
n
t
r
a
t
i
o
n
  5
  10
  15
  20
30
210
60
240
90
270
120
300
150
330
180 0
  5
  10
  15
  20
30
210
60
240
90
270
120
300
150
330
180 0
Neg. control
Pre-miR-145
0
10
20
30
40
50
0
10
20
30
40
50
60
Anti-miR-145
Neg. control
Anti-miR-145
Neg. control
M
e
a
n
 
d
i
s
t
a
n
c
e
p
e
r
 
c
e
l
l
 
(
µ
m
)
M
e
a
n
 
d
i
s
t
a
n
c
e
p
e
r
 
c
e
l
l
 
(
µ
m
)
Migration perpendicular
to gradient
0
10
20
30
40
50
60
0
10
20
30
40
50
60
70
80
P
D
G
F
-
B
B
 
c
o
n
c
e
n
t
r
a
t
i
o
n
  40
  60
  80
30
210
60
240
90
270
120
300
150
330
180 0
Anti-miR-145
P
D
G
F
-
B
B
 
c
o
n
c
e
n
t
r
a
t
i
o
n
  10
  60
  80
30
210
60
240
90
270
120
300
150
330
180 0
Neg. control
(c)
0
5
10
15
20
Pre-miR-145
Neg. control
M
i
g
r
a
t
e
d
 
d
i
s
t
a
n
c
e
 
(
a
.
u
.
)
B
r
d
U
 
i
n
c
o
r
p
o
r
a
t
i
o
n
(
a
b
s
o
r
b
a
n
c
e
 
a
t
 
4
5
0
 
n
m
)
P = 0.02
0
0.5
1
1.5
2
Neg. control
Pre-miR-145
Neg. control Pre-miR-145
Neg. control Pre-miR-145
0 h 0 h
24 h 24 hMigration was also evaluated on VAECs cultured in EC
growth factor supplemented medium using a wound healing
assay. Migration was reduced in Pre-miR-145 transfected
cells compared to cells transfected with a dsRNA control
(Stealth siRNA control, Invitrogen; Figure 6d). However,
proliferation rate, as determined using a BrdU ELISA assay,
was not affected. These findings point to a role for miR-145
in regulation of cell migration.
Discussion
By screening for mature miRNAs with vascular expression
patterns we found that miR-145, miR-126, miR-23a, and
miR-24 were enriched in the microvasculature in vivo.
miR-145 was specifically expressed in pericytes, whereas the
others were expressed in ECs. We demonstrated that the Ets
factor Fli1 is a regulatory target of miR-145 and that
perturbed levels of miR-145 reduced cell migration. The
present study provides insight into microvascular-selective
miRNA expression and differs from previous screens due to
its in vivo focus.
There is a notable overlap between high-scoring miRNAs in
our screen and those identified by several in vitro microarray
studies of HUVECs. Many of the miRNAs we identified scored
favorably in one or more of these screens, including miR-23a
[6-8,12], miR-23b [7,8,12], miR-24 [7,8,12] and miR-126
[6,8,12]. In addition, miR-23a, miR-23b, miR-24 and miR-
30d were shown to be upregulated in hypoxia [38]. miR-126,
for which an important functional role in the endothelium has
already been firmly established [8-11], stood out as strongly
enriched in microvascular fragments from mature mouse
tissues as well as in tissues undergoing active angiogenesis.
miR-145 has previously been shown to be selectively
expressed in smooth muscle cells [39-41]. It controls pheno-
typic modulation of these cells by inducing expression of
contractile proteins, an effect that is partly mediated by
targeting Klf5 [39,41]. Forced expression of pre-miR-145
also reduced neointimal formation after arterial injury [41].
Here, we show that miR-145 is expressed in microvascular
pericytes. miR-145 was expressed in scattered NG2-positive
cells tightly associated with the smallest caliber capillaries in
the brain and kidney. This staining pattern is typical for
pericytes and not compatible with vascular smooth muscle
cells. Furthermore, expression of miR-145 was reduced in
vascular fragments isolated from Pdgfbret/ret mice and
enriched in NG2+ cells isolated from embryoid bodies. We
did not, however, detect miR-145 in pericytes in the heart,
where expression was confined to larger arterioles.
Perturbed expression of miR-145 reduced cell migration in
cultured fibroblasts and ECs. This finding is supported by a
recent publication that describes miR-145 knockout mice
[40]. These mice show reduced neo-intima formation in
response to ligation of the carotid artery. The authors
suggest that the phenotype is caused by failed migration of
medial smooth muscle cells, although no migration experi-
ments were performed. In the same publication miR-145 is
shown to selectively target genes that regulate the actin
cytoskeleton, which is intimately coupled to cell migration.
Several target genes that regulate actin polymerization or
depolymerization were identified, some of which have been
shown to inhibit migration (Srgap1 and Srgap2) and others
that stimulate migration (Add3 and Ssh2). Many additional
target genes that affect actin dynamics were predicted, which
further supports a role for miR-145 in regulation of cell
motility. Paradoxically, migration was reduced by both over-
expression and silencing of miR-145 in our experiments. The
primary role of miR-145 may be to maintain cytoskeleton
homeostasis, and perturbed expression levels of miR-145, in
either direction, may disturb this balance and negatively
affect the cells’ ability to remodel the actin cytoskeleton. In
zebrafish, loss or gain-of-function experiments with miR-145
leads to identical phenotypes with poorly developed smooth
muscle cells in the gut [42].
Considering that miR-145 is selectively expressed by peri-
cytes, it is intriguing that the endothelial and hematopoietic
transcription factor Fli1 was identified as a target of miR-
145. Fli1 is an early marker of hemangioblast differentiation
and plays an important role in blood/vascular development
and angiogenesis [43-46]. Recent studies show that hemato-
poietic cells can emigrate from the circulation and differen-
tiate to pericytes [47-51]. It is tempting to speculate that
miR-145 could make such transitions sharp and distinct by
silencing the hematopoietic differentiation factor Fli1.
miRNA-based therapeutics is showing promise in animal
models and elevation or inhibition of miR-126 has been
proposed as a possible therapeutic strategy in ischemic heart
disease, cancer, retinopathy and stroke [9]. The miRNAs
identified in the present study - miR-145, miR-30D, miR-24,
miR-23a and miR-23b - are therefore possible targets in
future therapeutic strategies.
Conclusions
We identified miR-145, miR-126, miR-24 and miR-23a as
enriched in microvessels, and showed that microvascular
expression of miR-145 is due to its presence in pericytes. We
also performed a functional characterization of miR-145 and
could show that it is a regulator of Fli1, and that increased or
decreased expression of miR-145 leads to reduced cell
migration in response to growth factor gradients.
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